Company Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| IPO Date | Dec 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California United States | |
| Website | https://oncocyte.com |
Stock Details
| Ticker Symbol | OCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C107 |
| ISIN Number | US68235C2061 |
| Employer ID | 27-1041563 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer & Director |
| Andrea Susan James | Chief Financial Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Dr. Paul R. Billings FACP, M.D. | Consulting Chief Medical Officer |
| James Liu | Senior Director, Controller & Principal Accounting Officer |
| Peter Hong | Vice President, General Counsel & Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | 8-K | Current Report |
| Dec 27, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 27, 2024 | 4 | Filing |
| Dec 27, 2024 | 3 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Dec 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 09, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |